All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a healthcare professional.
The PsOPsA Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Introducing
Now you can personalise
your PsOPsA Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe PsOPsA Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the PsOPsA Hub cannot guarantee the accuracy of translated content. The PsOPsA Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The PsOPsA Hub is supported by educational grants. All educational content is developed independently by SES in collaboration with our expert steering committee, with no input or influence from financial supporters. We would like to express our gratitude to the following companies for their support: • UCB: For website development, launch, and ongoing maintenance. • UCB and Bristol Myers Squibb: For educational content and news updates.
#EADV2024: Psoriatic arthritis and rare psoriasis
By Ella Dixon
To update you on the exciting content presented at the 2024 European Academy of Dermatology and Venereology (EADV) Congress, we have collated our social media coverage. Catch up with our live social media posts relating to psoriatic arthritis and rarer forms of psoriasis below.
CONGRESS | #EADVCongress | PRESENTATION
— Psoriasis and Psoriatic Arthritis Hub (@psoriasis_hub) September 25, 2024
April Armstrong @_AprilArmstrong @DOM_UCLA examines how systemic psoriasis treatment may prevent the development of psoriatic arthritis.
They highlight clinical evidence supporting this preventative effect, and raise the need to consider… pic.twitter.com/ePwrfculZY
CONGRESS | #EADVCongress | PRESENTATION
— Psoriasis and Psoriatic Arthritis Hub (@psoriasis_hub) September 26, 2024
Jonathan Barker, St John’s Institute of Dermatology, UK, discusses whether pustular #psoriasis is a clinical continuum or separate entity, highlighting various subtypes and their similarities and differences in terms of demographics,… pic.twitter.com/B3WWS89l8V
CONGRESS | #EADVCongress | PRESENTATION
— Psoriasis and Psoriatic Arthritis Hub (@psoriasis_hub) September 26, 2024
Adam Reich, @UR_Rzeszow shares results from the phase III GEMINI-1 and GEMINI-2 trials of imsidolimab in patients with generalized pustular psoriasis.
Imsidolimab was well tolerated, with rapid and clinically meaningful improvement of GPP… pic.twitter.com/PdOYxNytbz
CONGRESS | #EADVCongress | PRESENTATION
— Psoriasis and Psoriatic Arthritis Hub (@psoriasis_hub) September 26, 2024
Mark Lebwohl, @IcahnMountSinai @MSHSDerm presents results from the phase IIIb/IV PSORIATYK SCALP trial assessing the safety and efficacy of deucravacitnib in patients with moderate-to-severe scalp psoriasis.
The primary endpoint was met,… pic.twitter.com/h9yLhUK9Fc
CONGRESS | #EADVCongress | PRESENTATION
— Psoriasis and Psoriatic Arthritis Hub (@psoriasis_hub) September 26, 2024
Georgios Kokolakis, @ChariteBerlin highlights findings from the SCRIPTOR study, which assessed the real-world sociodemographic and clinical characteristics of patients with generalized pustular psoriasis in Germany.
The use of guideline… pic.twitter.com/QqKIyj4lrh
CONGRESS | #EADVCongress | PRESENTATION
— Psoriasis and Psoriatic Arthritis Hub (@psoriasis_hub) September 27, 2024
Joseph Merola @JosephMerolaMD @UTSWMedCenter presents Week 32 results from the phase III DISCREET study of apremilast in patients with moderate-to-severe genital psoriasis.
After 32 weeks of treatment with apremilast, or 16 weeks of… pic.twitter.com/m31cxU2K2f
CONGRESS | #EADVCongress | PRESENTATION
— Psoriasis and Psoriatic Arthritis Hub (@psoriasis_hub) September 27, 2024
Alice Gottlieb, @IcahnMountSinai, presents results from a phase IIb trial (NCT05153148) evaluating the efficacy and safety of zasocitinib (TAK-279) in patients with active #psoriaticArthritis (N=290).
▪️ At Week 12, the primary endpoint of… pic.twitter.com/I4FvzMG22B
CONGRESS | #EADVCongress | PRESENTATION
— Psoriasis and Psoriatic Arthritis Hub (@psoriasis_hub) September 27, 2024
Siew Eng Choon, Sultanah Aminah Hospital, presents an international consensus definition and diagnostic criteria for generalized pustular #psoriasis developed by @IpcPs.
▪️ The established definition is: "GPP is a systemic inflammatory… pic.twitter.com/dIALaZtv18
CONGRESS | #EADVCongress | PRESENTATION
— Psoriasis and Psoriatic Arthritis Hub (@psoriasis_hub) September 27, 2024
Diamant Thaçi, @UniLuebeck, presents results from the phase IIIb/IV PSORIATYK SCALP trial (NCT05478499) evaluating the efficacy and safety of deucravacitinib in patients with moderate-to-severe scalp #psoriasis (N=154). At Week 16,… pic.twitter.com/vMshQMfq06
More about...
Your opinion matters
6 votes - 80 days left ...
Newsletter
Subscribe to get the best content related to Psoriasis and Psoriatic Arthritis delivered to your inbox